EPS for Omeros (OMER) Expected At $-0.53; SECURITAS A B ORDINARY SHARES SHS-B- (SCTBF) Shorts Down By 2.95%

April 22, 2018 - By Stephen Andrade

Securitas AB (OTCMKTS:SCTBF) Logo

Analysts expect Omeros Corporation (NASDAQ:OMER) to report $-0.53 EPS on May, 9.They anticipate $0.29 EPS change or 120.83% from last quarter’s $-0.24 EPS. After having $-0.25 EPS previously, Omeros Corporation’s analysts see 112.00% EPS growth. The stock decreased 6.03% or $0.9 during the last trading session, reaching $14.03. About 835,935 shares traded. Omeros Corporation (NASDAQ:OMER) has declined 3.39% since April 22, 2017 and is downtrending. It has underperformed by 14.94% the S&P500.

SECURITAS A B ORDINARY SHARES SHS-B- (OTCMKTS:SCTBF) had a decrease of 2.95% in short interest. SCTBF’s SI was 1.94 million shares in April as released by FINRA. Its down 2.95% from 2.00M shares previously. With 8,200 avg volume, 237 days are for SECURITAS A B ORDINARY SHARES SHS-B- (OTCMKTS:SCTBF)’s short sellers to cover SCTBF’s short positions. The SI to SECURITAS A B ORDINARY SHARES SHS-B-‘s float is 0.64%. It closed at $16.45 lastly. It is down 0.00% since April 22, 2017 and is . It has underperformed by 11.55% the S&P500.

Securitas AB provides security services in North America, Europe, Latin America, the Middle East, Asia, and Africa. The company has market cap of $6.17 billion. The firm operates through three divisions: Security Services North America, Security Services Europe, and Security Services Ibero-America. It has a 18 P/E ratio. It primarily offers specialized guarding, mobile, monitoring, remote video, on-site, electronic security, fire and safety, and corporate investigation and risk management services.

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company has market cap of $677.45 million. The firm markets OMIDRIA for use during cataract surgery or intraocular lens replacement. It currently has negative earnings. The Company’s clinical programs include OMS721 that is in Phase III clinical trial for the treatment of atypical hemolytic uremic syndrome; and in Phase II clinical trial to treat thrombotic microangiopathies, IgA nephropathy, and other renal diseases.

Since January 3, 2018, it had 0 insider buys, and 2 insider sales for $1.36 million activity. Kelbon Marcia S. also sold $1.34 million worth of Omeros Corporation (NASDAQ:OMER) shares. Shares for $22,899 were sold by JACOBSEN MICHAEL A.

Investors sentiment decreased to 1.3 in Q4 2017. Its down 1.56, from 2.86 in 2017Q3. It worsened, as 14 investors sold Omeros Corporation shares while 29 reduced holdings. 31 funds opened positions while 25 raised stakes. 21.94 million shares or 0.43% less from 22.04 million shares in 2017Q3 were reported. Winch Advisory Services Ltd Co reported 300 shares stake. Manufacturers Life Communication The invested in 0% or 65,197 shares. Ingalls And Snyder Lc has invested 4.77% of its portfolio in Omeros Corporation (NASDAQ:OMER). Stifel Fincl Corporation holds 0.02% or 342,192 shares in its portfolio. Cambridge Invest Advsrs invested in 16,745 shares or 0% of the stock. Moreover, Bankshares Of America De has 0% invested in Omeros Corporation (NASDAQ:OMER) for 77,591 shares. Tudor Invest Et Al holds 0.01% in Omeros Corporation (NASDAQ:OMER) or 12,716 shares. Gradient Invests Limited Com owns 503 shares. Moreover, Royal Bancorp Of Canada has 0% invested in Omeros Corporation (NASDAQ:OMER). California Public Employees Retirement Sys accumulated 54,400 shares. Morgan Stanley accumulated 157,503 shares or 0% of the stock. Fincl Grp Inc has 1.48% invested in Omeros Corporation (NASDAQ:OMER). Envestnet Asset Incorporated reported 0% of its portfolio in Omeros Corporation (NASDAQ:OMER). Cormorant Asset Management Limited Liability Company stated it has 875,000 shares or 1.78% of all its holdings. State Board Of Administration Of Florida Retirement has 30,737 shares.

Among 9 analysts covering Omeros (NASDAQ:OMER), 5 have Buy rating, 0 Sell and 4 Hold. Therefore 56% are positive. Omeros had 34 analyst reports since August 10, 2015 according to SRatingsIntel. The stock of Omeros Corporation (NASDAQ:OMER) earned “Buy” rating by H.C. Wainwright on Thursday, April 19. The firm has “Neutral” rating given on Thursday, May 11 by Cantor Fitzgerald. The stock of Omeros Corporation (NASDAQ:OMER) has “Buy” rating given on Monday, March 5 by H.C. Wainwright. The firm has “Buy” rating by Wedbush given on Tuesday, November 28. The stock of Omeros Corporation (NASDAQ:OMER) earned “Market Perform” rating by Cowen & Co on Thursday, November 2. The stock of Omeros Corporation (NASDAQ:OMER) earned “Hold” rating by Needham on Friday, March 2. The company was maintained on Wednesday, November 11 by Needham. As per Friday, June 3, the company rating was initiated by Cantor Fitzgerald. The stock of Omeros Corporation (NASDAQ:OMER) has “Buy” rating given on Thursday, March 22 by Maxim Group. On Wednesday, November 16 the stock rating was maintained by Wedbush with “Outperform”.

Omeros Corporation (NASDAQ:OMER) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: